

# Basic Drug List Updates

January 2022

TRADE NAME (generic name)	Brand/Generic Product	Description of Change
AJOVY (fremanezumab-vfrm subcutaneous soln auto-inj 225 mg/1.5ml)	Brand	Addition, Preferred Status
AJOVY (fremanezumab-vfrm subcutaneous soln pref syr 225 mg/1.5ml)	Brand	Addition, Preferred Status
CHANTIX (varenicline tartrate tab 0.5 mg (base equiv))	Brand	Removal, Non-Preferred Status
CHANTIX (varenicline tartrate tab 1 mg (base equiv))	Brand	Removal, Non-Preferred Status
CHANTIX CONTINUING MONTHPAK (varenicline tartrate tab 1 mg (base equiv))	Brand	Removal, Non-Preferred Status
CHANTIX STARTING MONTH PAK (varenicline tartrate tab 0.5 mg x 11 & tab 1 mg x 42 pack)	Brand	Removal, Non-Preferred Status
DUPIXENT (dupilumab subcutaneous soln pen-injector 200 mg/1.14ml)	Brand	Addition, Preferred Status
DUPIXENT (dupilumab subcutaneous soln pen-injector 300 mg/2ml)	Brand	Addition, Preferred Status
DUPIXENT (dupilumab subcutaneous soln prefilled syringe 200 mg/1.14ml)	Brand	Addition, Preferred Status
DUPIXENT (dupilumab subcutaneous soln prefilled syringe 300 mg/2ml)	Brand	Addition, Preferred Status
EMPAVELI (pegcetacoplan subcutaneous soln 1080 mg/20ml (54 mg/ml))	Brand	Addition, Preferred Status
FASENRA PEN (benralizumab subcutaneous soln auto-injector 30 mg/ml)	Brand	Addition, Preferred Status
INSULIN GLARGINE (insulin glargine-yfgn inj 100 unit/ml)	Brand	Addition, Preferred Status
INSULIN GLARGINE (insulin glargine-yfgn soln pen-injector 100 unit/ml)	Brand	Addition, Preferred Status
INVOKAMET (canagliflozin-metformin hcl tab 150-1000 mg)	Brand	Removal, Non-Preferred Status
INVOKAMET (canagliflozin-metformin hcl tab 150-500 mg)	Brand	Removal, Non-Preferred Status
INVOKAMET (canagliflozin-metformin hcl tab 50-1000 mg)	Brand	Removal, Non-Preferred Status
INVOKAMET (canagliflozin-metformin hcl tab 50-500 mg)	Brand	Removal, Non-Preferred Status
INVOKAMET XR (canagliflozin-metformin hcl tab er 24hr 150-1000 mg)	Brand	Removal, Non-Preferred Status
INVOKAMET XR (canagliflozin-metformin hcl tab er 24hr 150-500 mg)	Brand	Removal, Non-Preferred Status
INVOKAMET XR (canagliflozin-metformin hcl tab er 24hr 50-1000 mg)	Brand	Removal, Non-Preferred Status
INVOKAMET XR (canagliflozin-metformin hcl tab er 24hr 50-500 mg)	Brand	Removal, Non-Preferred Status
INVOKANA (canagliflozin tab 100 mg)	Brand	Removal, Non-Preferred Status
INVOKANA (canagliflozin tab 300 mg)	Brand	Removal, Non-Preferred Status
KLOXXADO (naloxone hcl nasal spray 8 mg/0.1ml)	Brand	Addition, Preferred Status
LANTUS (insulin glargine inj 100 unit/ml)	Brand	Removal, Non-Preferred Status
LANTUS SOLOSTAR (insulin glargine soln pen-injector 100 unit/ml)	Brand	Removal, Non-Preferred Status
MITIGARE (colchicine cap 0.6 mg)	Brand	Removal, Non-Preferred Status
NUCALA (mepolizumab subcutaneous solution auto-injector 100 mg/ml)	Brand	Addition, Preferred Status
NUCALA (mepolizumab subcutaneous solution pref syringe 100 mg/ml)	Brand	Addition, Preferred Status
NURTEC (rimegepant sulfate tab disint 75 mg)	Brand	Addition, Preferred Status
REYVOW (lasmiditan succinate tab 100 mg)	Brand	Addition, Preferred Status
REYVOW (lasmiditan succinate tab 50 mg)	Brand	Addition, Preferred Status
SEMGLEE (insulin glargine-yfgn inj 100 unit/ml)	Brand	Addition, Preferred Status
SEMGLEE (insulin glargine-yfgn soln pen-injector 100 unit/ml)	Brand	Addition, Preferred Status
SUPREP BOWEL PREP KIT (sod sulfate-pot sulf-mg sulf oral sol 17.5-3.13-1.6 gm/177ml)	Brand	Addition, Preferred Status
UBRELVY (ubrogepant tab 100 mg)	Brand	Addition, Preferred Status
UBRELVY (ubrogepant tab 50 mg)	Brand	Addition, Preferred Status
VARENICLINE TARTRATE (varenicline tartrate tab 0.5 mg (base equiv))	Brand	Addition, Preferred Status

Continued

<b>TRADE NAME (generic name)</b>	<b>Brand/Generic Product</b>	<b>Description of Change</b>
VARENICLINE TARTRATE (varenicline tartrate tab 1 mg (base equiv))	Brand	Addition, Preferred Status
XOLAIR (omalizumab subcutaneous soln prefilled syringe 150 mg/ml)	Brand	Addition, Preferred Status
XOLAIR (omalizumab subcutaneous soln prefilled syringe 75 mg/0.5ml)	Brand	Addition, Preferred Status

Blue Cross and Blue Shield of Illinois (BCBSIL), Blue Cross and Blue Shield of Montana (BCBSMT), Blue Cross and Blue Shield of New Mexico (BCBSNM), Blue Cross and Blue Shield of Oklahoma (BCBSOK), and Blue Cross and Blue Shield of Texas (BCBSTX) are Divisions of Health Care Service Corporation, a Mutual Legal Reserve Company, an Independent Licensee of the Blue Cross and Blue Shield Association. BCBSIL, BCBSMT, BCBSNM, BCBSOK, and BCBSTX contract with Prime Therapeutics to provide pharmacy benefit management and related other services. BCBSIL, BCBSMT, BCBSNM, BCBSOK, and BCBSTX, as well as several independent Blue Cross and Blue Shield Plans, have an ownership interest in Prime Therapeutics LLC.